107 related articles for article (PubMed ID: 19274615)
21. Distinct outcomes, ABL1 mutation profile, and transcriptome features between p190 and p210 transcripts in adult Philadelphia-positive acute lymphoblastic leukemia in the TKI era.
Shi T; Xie M; Chen L; Yuan W; Wang Y; Huang X; Xie W; Meng H; Lou Y; Yu W; Tong H; Ye X; Huang J; Jin J; Zhu H
Exp Hematol Oncol; 2022 Mar; 11(1):13. PubMed ID: 35277197
[TBL] [Abstract][Full Text] [Related]
22. Imatinib Efficacy, Safety and Resistance in Iranian Patients with Chronic Myeloid Leukemia: A Review of Literature.
Amouei A; Daeian N; Khezrnia SS; Mansouri A; Hadjibabaie M
Int J Hematol Oncol Stem Cell Res; 2021 Apr; 15(2):114-131. PubMed ID: 34466210
[No Abstract] [Full Text] [Related]
23. Aberrant DNA methylation at HOXA4 and HOXA5 genes are associated with resistance to imatinib mesylate among chronic myeloid leukemia patients.
Elias MH; Azlan H; Sulong S; Baba AA; Ankathil R
Cancer Rep (Hoboken); 2018 Aug; 1(2):e1111. PubMed ID: 32721103
[TBL] [Abstract][Full Text] [Related]
24. Practical Laboratory Tools for Monitoring of BCR-ABL1 Transcripts and Tyrosine Kinase (TK) Domain Mutations in Chronic Myeloid Leukemia Patients Undergoing TK Inhibitor Therapy: A Single-Center Experience in Thailand.
Limsuwanachot N; Kongruang A; Rerkamnuaychoke B; Singdong R; Niparuck P; Jootar S; Siriboonpiputtana T
Asian Pac J Cancer Prev; 2020 Jul; 21(7):2003-2012. PubMed ID: 32711426
[TBL] [Abstract][Full Text] [Related]
25. Multi-scale Predictions of Drug Resistance Epidemiology Identify Design Principles for Rational Drug Design.
Leighow SM; Liu C; Inam H; Zhao B; Pritchard JR
Cell Rep; 2020 Mar; 30(12):3951-3963.e4. PubMed ID: 32209458
[TBL] [Abstract][Full Text] [Related]
26. GCA links TRAF6-ULK1-dependent autophagy activation in resistant chronic myeloid leukemia.
Han SH; Korm S; Han YG; Choi SY; Kim SH; Chung HJ; Park K; Kim JY; Myung K; Lee JY; Kim H; Kim DW
Autophagy; 2019 Dec; 15(12):2076-2090. PubMed ID: 30929559
[TBL] [Abstract][Full Text] [Related]
27. The third-time chronic myeloid leukemia in lymphoblastic crisis with ABL1 kinase mutation induced by decitabine, dexamethason combined with nilotinib and dasatinib.
Wang S; Qiao C; Zhu Y; Shen W; He G; Li J
J Transl Int Med; 2016 Dec; 4(4):182-184. PubMed ID: 28191543
[TBL] [Abstract][Full Text] [Related]
28. Incidence and clinical importance of BCR-ABL1 mutations in Iranian patients with chronic myeloid leukemia on imatinib.
Rostami G; Hamid M; Yaran M; Khani M; Karimipoor M
J Hum Genet; 2015 May; 60(5):253-8. PubMed ID: 25740611
[TBL] [Abstract][Full Text] [Related]
29. Evolution of BCR/ABL gene mutation in CML is time dependent and dependent on the pressure exerted by tyrosine kinase inhibitor.
Vaidya S; Vundinti BR; Shanmukhaiah C; Chakrabarti P; Ghosh K
PLoS One; 2015; 10(1):e0114828. PubMed ID: 25629972
[TBL] [Abstract][Full Text] [Related]
30. Increased genomic instability may contribute to the development of kinase domain mutations in chronic myeloid leukemia.
Sweet K; Al Ali NH; Dalia SM; Komrokji RS; Crescentini RM; Tinsley S; Lancet JE; Papenhausen PR; Zhang L; Pinilla-Ibarz J
Int J Hematol; 2014 Dec; 100(6):567-74. PubMed ID: 25281405
[TBL] [Abstract][Full Text] [Related]
31. Incidence of Bcr-Abl kinase domain mutations in imatinib refractory chronic myeloid leukemia patients from South India.
Kagita S; Uppalapati S; Jiwatani S; Linga VG; Gundeti S; Nagesh N; Digumarti R
Tumour Biol; 2014 Jul; 35(7):7187-93. PubMed ID: 24763825
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors.
Kim SH; Menon H; Jootar S; Saikia T; Kwak JY; Sohn SK; Park JS; Jeong SH; Kim HJ; Kim YK; Oh SJ; Kim H; Zang DY; Chung JS; Shin HJ; Do YR; Kim JA; Kim DY; Choi CW; Park S; Park HL; Lee GY; Cho DJ; Shin JS; Kim DW
Haematologica; 2014 Jul; 99(7):1191-6. PubMed ID: 24705186
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of dasatinib versus imatinib in the East Asian subpopulation of the DASISION trial of newly diagnosed chronic myeloid leukemia in chronic phase.
Chuah CT; Nakamae H; Shen ZX; Bradley-Garelik MB; Kim DW
Leuk Lymphoma; 2014 Sep; 55(9):2093-100. PubMed ID: 24289108
[TBL] [Abstract][Full Text] [Related]
34. A single-tube allele specific-polymerase chain reaction to detect T315I resistant mutation in chronic myeloid leukemia patients.
Wongboonma W; Thongnoppakhun W; Auewarakul CU
J Hematol Oncol; 2011 Feb; 4():7. PubMed ID: 21303525
[TBL] [Abstract][Full Text] [Related]
35. Imatinib and docetaxel in combination can effectively inhibit glioma invasion in an in vitro 3D invasion assay.
Kinsella P; Clynes M; Amberger-Murphy V
J Neurooncol; 2011 Jan; 101(2):189-98. PubMed ID: 20512610
[TBL] [Abstract][Full Text] [Related]
36. Analysis of Bcr-Abl kinase domain mutations in Korean chronic myeloid leukaemia patients: poor clinical outcome of P-loop and T315I mutation is disease phase dependent.
Kim SH; Kim D; Kim DW; Goh HG; Jang SE; Lee J; Kim WS; Kweon IY; Park SH
Hematol Oncol; 2009 Dec; 27(4):190-7. PubMed ID: 19274615
[TBL] [Abstract][Full Text] [Related]
37. BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome.
Elias MH; Baba AA; Azlan H; Rosline H; Sim GA; Padmini M; Fadilah SA; Ankathil R
Leuk Res; 2014 Apr; 38(4):454-9. PubMed ID: 24456693
[TBL] [Abstract][Full Text] [Related]
38. Dynamic change of T315I BCR-ABL kinase domain mutation in Korean chronic myeloid leukaemia patients during treatment with Abl tyrosine kinase inhibitors.
Kim WS; Kim D; Kim DW; Kweon IY; Kim SH; Goh HG; Park SH; Lee J
Hematol Oncol; 2010 Jun; 28(2):82-8. PubMed ID: 19768693
[TBL] [Abstract][Full Text] [Related]
39. Presence of novel compound BCR-ABL mutations in late chronic and advanced phase imatinib sensitive CML patients indicates their possible role in CML progression.
Akram AM; Iqbal Z; Akhtar T; Khalid AM; Sabar MF; Qazi MH; Aziz Z; Sajid N; Aleem A; Rasool M; Asif M; Aloraibi S; Aljamaan K; Iqbal M
Cancer Biol Ther; 2017 Apr; 18(4):214-221. PubMed ID: 28278078
[TBL] [Abstract][Full Text] [Related]
40. New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check.
O'Hare T; Eide CA; Deininger MW
Expert Opin Investig Drugs; 2008 Jun; 17(6):865-78. PubMed ID: 18491988
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
